Listed

IRulya Therapeutics Inc.

IRLANasdaqCIK 1662774HealthcareFiscal year ends Dec 31

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Income statement

Operating income−$79.8m, Q2 FY2026
Net income−$75.5m, Q2 FY2026
IRulya Therapeutics Inc., income statement, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Research and development$m1.4Research and development, Q3 FY2023, three months to 2023-09-30$1.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure3.4Research and development, Q4 FY2023, three months to 2023-12-31$3.4m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2025-03-24, accession 0001662774-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure3.7Research and development, Q1 FY2024, three months to 2024-03-31$3.7m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure4.1Research and development, Q2 FY2024, three months to 2024-06-30$4.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure4.9Research and development, Q3 FY2024, three months to 2024-09-30$4.9m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure5.8Research and development, Q4 FY2024, three months to 2024-12-31$5.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure8.1Research and development, Q1 FY2025, three months to 2025-03-31$8.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure6.6Research and development, Q2 FY2025, three months to 2025-06-30$6.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure8.1Research and development, Q3 FY2025, three months to 2025-09-30$8.1m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure12.6Research and development, Q4 FY2025, three months to 2025-12-31$12.6m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure6.8Research and development, Q1 FY2026, three months to 2026-03-31$6.8m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure5.5Research and development, Q2 FY2026, three months to 2026-06-30$5.5m. XBRL concept us-gaap:ResearchAndDevelopmentExpense. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Operating income$m(6.1)Operating income, Q3 FY2023, three months to 2023-09-30−$6.1m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure(9.9)Operating income, Q4 FY2023, three months to 2023-12-31−$9.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2025-03-24, accession 0001662774-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure(11.2)Operating income, Q1 FY2024, three months to 2024-03-31−$11.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure(28.2)Operating income, Q2 FY2024, three months to 2024-06-30−$28.2m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure(5.9)Operating income, Q3 FY2024, three months to 2024-09-30−$5.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure(12.0)Operating income, Q4 FY2024, three months to 2024-12-31−$12.0m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure(14.9)Operating income, Q1 FY2025, three months to 2025-03-31−$14.9m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(10.4)Operating income, Q2 FY2025, three months to 2025-06-30−$10.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure(13.4)Operating income, Q3 FY2025, three months to 2025-09-30−$13.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure(19.4)Operating income, Q4 FY2025, three months to 2025-12-31−$19.4m. XBRL concept us-gaap:OperatingIncomeLoss. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure(14.6)Operating income, Q1 FY2026, three months to 2026-03-31−$14.6m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(79.8)Operating income, Q2 FY2026, three months to 2026-06-30−$79.8m. XBRL concept us-gaap:OperatingIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Interest expense$mnot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reportednot reported
Income tax$m0.0Income tax, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure0.1Income tax, Q4 FY2023, three months to 2023-12-31$51.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2025-03-24, accession 0001662774-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2024, three months to 2024-03-31$31.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure0.0Income tax, Q2 FY2024, three months to 2024-06-30$36.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure0.0Income tax, Q3 FY2024, three months to 2024-09-30$13.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure0.0Income tax, Q4 FY2024, three months to 2024-12-31$7.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure0.0Income tax, Q1 FY2025, three months to 2025-03-31$47.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure0.1Income tax, Q2 FY2025, three months to 2025-06-30$67.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure(0.0)Income tax, Q3 FY2025, three months to 2025-09-30−$46.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure3.1Income tax, Q4 FY2025, three months to 2025-12-31$3.1m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure(5.3)Income tax, Q1 FY2026, three months to 2026-03-31−$5.3m. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure0.1Income tax, Q2 FY2026, three months to 2026-06-30$75.0k. XBRL concept us-gaap:IncomeTaxExpenseBenefit. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Net income$m(5.4)Net income, Q3 FY2023, three months to 2023-09-30−$5.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure(8.9)Net income, Q4 FY2023, three months to 2023-12-31−$8.9m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-03-24, accession 0001662774-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure(11.1)Net income, Q1 FY2024, three months to 2024-03-31−$11.1m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure(27.7)Net income, Q2 FY2024, three months to 2024-06-30−$27.7m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure(5.5)Net income, Q3 FY2024, three months to 2024-09-30−$5.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure(12.5)Net income, Q4 FY2024, three months to 2024-12-31−$12.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure(15.0)Net income, Q1 FY2025, three months to 2025-03-31−$15.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(16.0)Net income, Q2 FY2025, three months to 2025-06-30−$16.0m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure(13.4)Net income, Q3 FY2025, three months to 2025-09-30−$13.4m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure(39.5)Net income, Q4 FY2025, three months to 2025-12-31−$39.5m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure35.9Net income, Q1 FY2026, three months to 2026-03-31$35.9m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(75.5)Net income, Q2 FY2026, three months to 2026-06-30−$75.5m. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Diluted EPS$ per share(0.15)Diluted EPS, Q3 FY2023, three months to 2023-09-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figurenot reported(0.26)Diluted EPS, Q1 FY2024, three months to 2024-03-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure(0.64)Diluted EPS, Q2 FY2024, three months to 2024-06-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure(0.13)Diluted EPS, Q3 FY2024, three months to 2024-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figurenot reported(3.42)Diluted EPS, Q1 FY2025, three months to 2025-03-31−$3.42 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(68.75)Diluted EPS, Q2 FY2025, three months to 2025-06-30−$68.75 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure(0.25)Diluted EPS, Q3 FY2025, three months to 2025-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figurenot reported2.88Diluted EPS, Q1 FY2026, three months to 2026-03-31$2.88 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(12.31)Diluted EPS, Q2 FY2026, three months to 2026-06-30−$12.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Basic EPS$ per share(0.15)Basic EPS, Q3 FY2023, three months to 2023-09-30−$0.15 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figurenot reported(0.26)Basic EPS, Q1 FY2024, three months to 2024-03-31−$0.26 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure(0.64)Basic EPS, Q2 FY2024, three months to 2024-06-30−$0.64 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure(0.13)Basic EPS, Q3 FY2024, three months to 2024-09-30−$0.13 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figurenot reported(3.42)Basic EPS, Q1 FY2025, three months to 2025-03-31−$3.42 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(68.75)Basic EPS, Q2 FY2025, three months to 2025-06-30−$68.75 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure(0.25)Basic EPS, Q3 FY2025, three months to 2025-09-30−$0.25 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figurenot reported3.60Basic EPS, Q1 FY2026, three months to 2026-03-31$3.60 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(12.31)Basic EPS, Q2 FY2026, three months to 2026-06-30−$12.31 per share. XBRL concept us-gaap:EarningsPerShareBasic. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure

Balance sheet

Cash and equivalents$116.0m, Q2 FY2026
Long-term debt$0, FY2025
Shareholders' equity−$35.3m, Q2 FY2026
IRulya Therapeutics Inc., balance sheet, quarterly
Line itemUnitQ3 FY20232023-09-30FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Cash and equivalents$m20.8Cash and equivalents, Q3 FY2023, at 2023-09-30$20.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2023-11-14, accession 0000950170-23-063716.Report this figurenot reportednot reportednot reportednot reported6.2Cash and equivalents, FY2024, at 2024-12-31$6.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-K filed 2026-04-10, accession 0001193125-26-151364.Report this figure7.8Cash and equivalents, Q1 FY2025, at 2025-03-31$7.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure16.8Cash and equivalents, Q2 FY2025, at 2025-06-30$16.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure6.5Cash and equivalents, Q3 FY2025, at 2025-09-30$6.5m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure5.8Cash and equivalents, FY2025, at 2025-12-31$5.8m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure18.2Cash and equivalents, Q1 FY2026, at 2026-03-31$18.2m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure116Cash and equivalents, Q2 FY2026, at 2026-06-30$116.0m. XBRL concept us-gaap:CashAndCashEquivalentsAtCarryingValue. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Current assets$m85.2Current assets, Q3 FY2023, at 2023-09-30$85.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063716.Report this figure77.4Current assets, FY2023, at 2023-12-31$77.4m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2025-03-24, accession 0001662774-25-000012.Report this figure70.4Current assets, Q1 FY2024, at 2024-03-31$70.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-05-13, accession 0000950170-24-058201.Report this figure63.4Current assets, Q2 FY2024, at 2024-06-30$63.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-08-13, accession 0001662774-24-000005.Report this figure51.7Current assets, Q3 FY2024, at 2024-09-30$51.7m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure44.0Current assets, FY2024, at 2024-12-31$44.0m. XBRL concept us-gaap:AssetsCurrent. 10-K filed 2026-04-10, accession 0001193125-26-151364.Report this figure33.8Current assets, Q1 FY2025, at 2025-03-31$33.8m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure37.3Current assets, Q2 FY2025, at 2025-06-30$37.3m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure29.2Current assets, Q3 FY2025, at 2025-09-30$29.2m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure22.9Current assets, FY2025, at 2025-12-31$22.9m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure25.6Current assets, Q1 FY2026, at 2026-03-31$25.6m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure123Current assets, Q2 FY2026, at 2026-06-30$123.4m. XBRL concept us-gaap:AssetsCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Total assets$m85.4Total assets, Q3 FY2023, at 2023-09-30$85.4m. XBRL concept us-gaap:Assets. 10-Q filed 2023-11-14, accession 0000950170-23-063716.Report this figure168Total assets, FY2023, at 2023-12-31$167.9m. XBRL concept us-gaap:Assets. 10-K filed 2025-03-24, accession 0001662774-25-000012.Report this figure159Total assets, Q1 FY2024, at 2024-03-31$159.3m. XBRL concept us-gaap:Assets. 10-Q filed 2024-05-13, accession 0000950170-24-058201.Report this figure135Total assets, Q2 FY2024, at 2024-06-30$134.8m. XBRL concept us-gaap:Assets. 10-Q filed 2024-08-13, accession 0001662774-24-000005.Report this figure127Total assets, Q3 FY2024, at 2024-09-30$126.5m. XBRL concept us-gaap:Assets. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure114Total assets, FY2024, at 2024-12-31$114.5m. XBRL concept us-gaap:Assets. 10-K filed 2026-04-10, accession 0001193125-26-151364.Report this figure107Total assets, Q1 FY2025, at 2025-03-31$107.1m. XBRL concept us-gaap:Assets. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure117Total assets, Q2 FY2025, at 2025-06-30$117.2m. XBRL concept us-gaap:Assets. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure110Total assets, Q3 FY2025, at 2025-09-30$109.9m. XBRL concept us-gaap:Assets. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure93.5Total assets, FY2025, at 2025-12-31$93.5m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure26.6Total assets, Q1 FY2026, at 2026-03-31$26.6m. XBRL concept us-gaap:Assets. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure124Total assets, Q2 FY2026, at 2026-06-30$124.0m. XBRL concept us-gaap:Assets. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Current liabilities$m2.3Current liabilities, Q3 FY2023, at 2023-09-30$2.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2023-11-14, accession 0000950170-23-063716.Report this figure9.6Current liabilities, FY2023, at 2023-12-31$9.6m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2025-03-24, accession 0001662774-25-000012.Report this figure9.8Current liabilities, Q1 FY2024, at 2024-03-31$9.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-05-13, accession 0000950170-24-058201.Report this figure10.3Current liabilities, Q2 FY2024, at 2024-06-30$10.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-08-13, accession 0001662774-24-000005.Report this figure5.4Current liabilities, Q3 FY2024, at 2024-09-30$5.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure7.3Current liabilities, FY2024, at 2024-12-31$7.3m. XBRL concept us-gaap:LiabilitiesCurrent. 10-K filed 2026-04-10, accession 0001193125-26-151364.Report this figure8.4Current liabilities, Q1 FY2025, at 2025-03-31$8.4m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure7.5Current liabilities, Q2 FY2025, at 2025-06-30$7.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure26.0Current liabilities, Q3 FY2025, at 2025-09-30$26.0m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure43.2Current liabilities, FY2025, at 2025-12-31$43.2m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure8.8Current liabilities, Q1 FY2026, at 2026-03-31$8.8m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure8.5Current liabilities, Q2 FY2026, at 2026-06-30$8.5m. XBRL concept us-gaap:LiabilitiesCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Total liabilities$m2.3Total liabilities, Q3 FY2023, at 2023-09-30$2.3m. XBRL concept us-gaap:Liabilities. 10-Q filed 2023-11-14, accession 0000950170-23-063716.Report this figure82.8Total liabilities, FY2023, at 2023-12-31$82.8m. XBRL concept us-gaap:Liabilities. 10-K filed 2025-03-24, accession 0001662774-25-000012.Report this figure85.1Total liabilities, Q1 FY2024, at 2024-03-31$85.1m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-05-13, accession 0000950170-24-058201.Report this figure87.9Total liabilities, Q2 FY2024, at 2024-06-30$87.9m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-08-13, accession 0001662774-24-000005.Report this figure81.6Total liabilities, Q3 FY2024, at 2024-09-30$81.6m. XBRL concept us-gaap:Liabilities. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure84.3Total liabilities, FY2024, at 2024-12-31$84.3m. XBRL concept us-gaap:Liabilities. 10-K filed 2026-04-10, accession 0001193125-26-151364.Report this figure88.5Total liabilities, Q1 FY2025, at 2025-03-31$88.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure105Total liabilities, Q2 FY2025, at 2025-06-30$105.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure109Total liabilities, Q3 FY2025, at 2025-09-30$108.8m. XBRL concept us-gaap:Liabilities. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure129Total liabilities, FY2025, at 2025-12-31$129.2m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure11.0Total liabilities, Q1 FY2026, at 2026-03-31$11.0m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure15.5Total liabilities, Q2 FY2026, at 2026-06-30$15.5m. XBRL concept us-gaap:Liabilities. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Long-term debt$mnot reported13.4Long-term debt, FY2023, at 2023-12-31$13.4m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2025-03-24, accession 0001662774-25-000012.Report this figure13.5Long-term debt, Q1 FY2024, at 2024-03-31$13.5m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-05-13, accession 0000950170-24-058201.Report this figure13.8Long-term debt, Q2 FY2024, at 2024-06-30$13.8m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-08-13, accession 0001662774-24-000005.Report this figure14.9Long-term debt, Q3 FY2024, at 2024-09-30$14.9m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure14.3Long-term debt, FY2024, at 2024-12-31$14.3m. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-04-10, accession 0001193125-26-151364.Report this figure15.3Long-term debt, Q1 FY2025, at 2025-03-31$15.3m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure17.0Long-term debt, Q2 FY2025, at 2025-06-30$17.0m. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure0.0Long-term debt, Q3 FY2025, at 2025-09-30$0. XBRL concept us-gaap:LongTermDebt. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure0.0Long-term debt, FY2025, at 2025-12-31$0. XBRL concept us-gaap:LongTermDebt. 10-K filed 2026-04-10, accession 0001193125-26-151364.Report this figurenot reportednot reported
Current portion of debt$mnot reportednot reportednot reportednot reportednot reported0.0Current portion of debt, FY2024, at 2024-12-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-K filed 2026-04-10, accession 0001193125-26-151364.Report this figurenot reportednot reported17.5Current portion of debt, Q3 FY2025, at 2025-09-30$17.5m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure18.0Current portion of debt, FY2025, at 2025-12-31$18.0m. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure0.0Current portion of debt, Q1 FY2026, at 2026-03-31$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure0.0Current portion of debt, Q2 FY2026, at 2026-06-30$0. XBRL concept us-gaap:LongTermDebtCurrent. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure
Shareholders' equity$m83.1Shareholders' equity, Q3 FY2023, at 2023-09-30$83.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure85.1Shareholders' equity, FY2023, at 2023-12-31$85.1m. XBRL concept us-gaap:StockholdersEquity. 10-K filed 2026-04-10, accession 0001193125-26-151364.Report this figure74.2Shareholders' equity, Q1 FY2024, at 2024-03-31$74.2m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure47.0Shareholders' equity, Q2 FY2024, at 2024-06-30$47.0m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure44.9Shareholders' equity, Q3 FY2024, at 2024-09-30$44.9m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure30.1Shareholders' equity, FY2024, at 2024-12-31$30.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure18.6Shareholders' equity, Q1 FY2025, at 2025-03-31$18.6m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure11.7Shareholders' equity, Q2 FY2025, at 2025-06-30$11.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure1.1Shareholders' equity, Q3 FY2025, at 2025-09-30$1.1m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure(35.7)Shareholders' equity, FY2025, at 2025-12-31−$35.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure15.7Shareholders' equity, Q1 FY2026, at 2026-03-31$15.7m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure(35.3)Shareholders' equity, Q2 FY2026, at 2026-06-30−$35.3m. XBRL concept us-gaap:StockholdersEquity. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure

Cash flow

Operating cash flow−$18.9m, Q2 FY2026
Capital expenditure$0, Q2 FY2026
IRulya Therapeutics Inc., cash flow, quarterly
Line itemUnitQ3 FY20232023-09-30Q4 FY20232023-12-31Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30
Operating cash flow$m(4.8)Operating cash flow, Q3 FY2023, three months to 2023-09-30−$4.8m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2024-11-13, accession 0001662774-24-000011. Derived: 9-month figure less the 6-month figure.Report this figure(6.1)Operating cash flow, Q4 FY2023, three months to 2023-12-31−$6.1m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-03-24, accession 0001662774-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure(8.4)Operating cash flow, Q1 FY2024, three months to 2024-03-31−$8.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure(8.7)Operating cash flow, Q2 FY2024, three months to 2024-06-30−$8.7m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-08-11, accession 0000950170-25-106535. Derived: 6-month figure less the 3-month figure.Report this figure(7.3)Operating cash flow, Q3 FY2024, three months to 2024-09-30−$7.3m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277529. Derived: 9-month figure less the 6-month figure.Report this figure(7.6)Operating cash flow, Q4 FY2024, three months to 2024-12-31−$7.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure(9.6)Operating cash flow, Q1 FY2025, three months to 2025-03-31−$9.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(11.4)Operating cash flow, Q2 FY2025, three months to 2025-06-30−$11.4m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-352201. Derived: 6-month figure less the 3-month figure.Report this figure(9.9)Operating cash flow, Q3 FY2025, three months to 2025-09-30−$9.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-11-12, accession 0001193125-25-277529. Derived: 9-month figure less the 6-month figure.Report this figure(10.5)Operating cash flow, Q4 FY2025, three months to 2025-12-31−$10.5m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure(7.6)Operating cash flow, Q1 FY2026, three months to 2026-03-31−$7.6m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure(18.9)Operating cash flow, Q2 FY2026, three months to 2026-06-30−$18.9m. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-08-14, accession 0001193125-26-352201. Derived: 6-month figure less the 3-month figure.Report this figure
Capital expenditure$m0.0Capital expenditure, Q3 FY2023, three months to 2023-09-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2024-11-13, accession 0001662774-24-000011. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2023, three months to 2023-12-31$24.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-03-24, accession 0001662774-25-000012. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2024, three months to 2024-03-31$39.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure0.0Capital expenditure, Q2 FY2024, three months to 2024-06-30$39.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-08-11, accession 0000950170-25-106535. Derived: 6-month figure less the 3-month figure.Report this figure0.0Capital expenditure, Q3 FY2024, three months to 2024-09-30$46.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277529. Derived: 9-month figure less the 6-month figure.Report this figure0.1Capital expenditure, Q4 FY2024, three months to 2024-12-31$133.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure0.1Capital expenditure, Q1 FY2025, three months to 2025-03-31$148.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure0.1Capital expenditure, Q2 FY2025, three months to 2025-06-30$126.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001193125-26-352201. Derived: 6-month figure less the 3-month figure.Report this figure0.1Capital expenditure, Q3 FY2025, three months to 2025-09-30$74.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-11-12, accession 0001193125-25-277529. Derived: 9-month figure less the 6-month figure.Report this figure0.0Capital expenditure, Q4 FY2025, three months to 2025-12-31$4.0k. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-04-10, accession 0001193125-26-151364. Derived: 12-month figure less the 9-month figure.Report this figure0.0Capital expenditure, Q1 FY2026, three months to 2026-03-31$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure0.0Capital expenditure, Q2 FY2026, three months to 2026-06-30$0. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-08-14, accession 0001193125-26-352201. Derived: 6-month figure less the 3-month figure.Report this figure

Shares

Diluted shares (weighted)6.13m, Q2 FY2026
IRulya Therapeutics Inc., shares, quarterly
Line itemUnitQ3 FY20222022-09-30Q1 FY20232023-03-31Q2 FY20232023-06-30Q3 FY20232023-09-30Q1 FY20242024-03-31Q2 FY20242024-06-30Q3 FY20242024-09-30Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q1 FY20262026-03-31Q2 FY20262026-06-30
Diluted shares (weighted)m shares35.6Diluted shares (weighted), Q3 FY2022, three months to 2022-09-3035,612,749 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2023-11-14, accession 0000950170-23-063716.Report this figure35.9Diluted shares (weighted), Q1 FY2023, three months to 2023-03-3135,855,200 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-05-13, accession 0000950170-24-058201.Report this figure35.9Diluted shares (weighted), Q2 FY2023, three months to 2023-06-3035,917,592 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-08-13, accession 0001662774-24-000005.Report this figure36.1Diluted shares (weighted), Q3 FY2023, three months to 2023-09-3036,073,040 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2024-11-13, accession 0001662774-24-000011.Report this figure43.0Diluted shares (weighted), Q1 FY2024, three months to 2024-03-3143,010,212 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-05-13, accession 0001662774-25-000032.Report this figure43.1Diluted shares (weighted), Q2 FY2024, three months to 2024-06-3043,096,374 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-08-11, accession 0000950170-25-106535.Report this figure43.2Diluted shares (weighted), Q3 FY2024, three months to 2024-09-3043,164,136 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure4.4Diluted shares (weighted), Q1 FY2025, three months to 2025-03-314,394,119 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure0.2Diluted shares (weighted), Q2 FY2025, three months to 2025-06-30233,431 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure54.0Diluted shares (weighted), Q3 FY2025, three months to 2025-09-3053,951,371 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2025-11-12, accession 0001193125-25-277529.Report this figure9.2Diluted shares (weighted), Q1 FY2026, three months to 2026-03-319,190,354 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-05-11, accession 0001193125-26-217098.Report this figure6.1Diluted shares (weighted), Q2 FY2026, three months to 2026-06-306,132,845 shares. XBRL concept us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure

Shares outstanding: 1.02mShares outstanding, period not labelled, at 2026-08-071,017,063 shares. XBRL concept dei:EntityCommonStockSharesOutstanding. 10-Q filed 2026-08-14, accession 0001193125-26-352201.Report this figure at Aug 7, 2026, from the cover of the 10-Q filed Aug 14, 2026.

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. Listed shows no prices and gives no investment advice.